Omeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript

Dr. Greg Demopulos: And I think I am sure that Rayner realizes that and is focused as they should be on expanding Med Advantage payments, not just coverage, but payment. And there are ways, I think, that the Congressional action can carry through and we have looked at that as well, that that can carry through to Med Advantage and help educate the Med Advantage payers, which often are the same payers as commercial as to why they should be separately paying for OMIDRIA in the same way that Congress has mandated CMS too.

Serge Belanger: Yeah. Thanks.

Dr. Greg Demopulos: All right, Serge.

Operator: And thank you. And I am showing no further questions. I would now like to turn the call back over to Dr. Demopulos for closing remarks.

Dr. Greg Demopulos: All right. Thank you very much, Operator. Once again thank you everyone for joining us today. As I think you can see and as I think we were just discussing some of the analysts, Omeros is well positioned financially to develop the deep pipeline of assets that we control. So with multiple and frequent near- and mid-term milestone events, the financial strength that Omeros now has really despite the tumultuous times globally and macroeconomically will allow us to remain focused throughout 2023 and beyond on really bringing life saving products to patients and value to our shareholders. We will continue to keep you updated on our progress. As always, we appreciate your continued support. Have a good evening.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.